![Bruno Oesch](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Bruno Oesch is the founder.
He founded Prionics AG in 1997 and served as the Co-Chief Executive Officer in 2011.
He also founded Neurotune AG in 2005 and currently serves as the Chairman.
Additionally, he founded Malcisbo AG in 2010 and currently holds the position of Chief Executive Officer & Director.
Dr. Oesch's former job was as a Principal at The University of California, San Francisco.
He obtained a doctorate degree from the University of Zurich and a graduate degree from the Swiss Federal Institute of Technology.
Aktive Positionen von Bruno Oesch
Unternehmen | Position | Beginn |
---|---|---|
Neurotune AG
![]() Neurotune AG Pharmaceuticals: MajorHealth Technology Neurotune AG develops medications for neuropathic pain and sarcopenia. The firm is developing treatments which modulate the connections between nerve cells and its target cells. The company was founded by Bruno Oesch in January 2005 and is headquartered in Schlieren-Zurich, Switzerland. | Gründer | 01.01.2005 |
Malcisbo AG
![]() Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | Gründer | 01.05.2010 |
Ehemalige bekannte Positionen von Bruno Oesch
Unternehmen | Position | Ende |
---|---|---|
The University of California, San Francisco | Corporate Officer/Principal | - |
Prionics AG
![]() Prionics AG Medical SpecialtiesHealth Technology Prionics AG engages in the research in as well as the development, production, and distribution of diagnostic solutions for farm animal diseases. It focuses on diseases that can be transmitted from animals to human beings such as mad cow's disease and other prion diseases. The company was founded by Bruno Oesch and Markus Moser on February 27, 1997 and is headquartered in Schlieren, Switzerland. | Gründer | - |
Ausbildung von Bruno Oesch
Swiss Federal Institute of Technology | Graduate Degree |
University of Zurich | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
Neurotune AG
![]() Neurotune AG Pharmaceuticals: MajorHealth Technology Neurotune AG develops medications for neuropathic pain and sarcopenia. The firm is developing treatments which modulate the connections between nerve cells and its target cells. The company was founded by Bruno Oesch in January 2005 and is headquartered in Schlieren-Zurich, Switzerland. | Health Technology |
Prionics AG
![]() Prionics AG Medical SpecialtiesHealth Technology Prionics AG engages in the research in as well as the development, production, and distribution of diagnostic solutions for farm animal diseases. It focuses on diseases that can be transmitted from animals to human beings such as mad cow's disease and other prion diseases. The company was founded by Bruno Oesch and Markus Moser on February 27, 1997 and is headquartered in Schlieren, Switzerland. | Health Technology |
Malcisbo AG
![]() Malcisbo AG Pharmaceuticals: MajorHealth Technology Malcisbo AG engages in the development of novel carbohydrate-based vaccines for human and animal health. It specializes in glycoengineering technologies to create novel and efficient glycoconjugate vaccines for unmet needs in human and veterinary medicine targeting large markets. Its vaccines target the medical areas of human Campylobacter infections and and porcine Actinobacillus pleuropneumoniae infections. The company was founded by Bruno Oesch, Irene Schiller, Markus Aebi and Lino Camponovo in May 2010 and is headquartered in Schlieren, Switzerland. | Health Technology |